{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:20:14Z","timestamp":1788337214321,"version":"build-2803163510"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Digit. Health"],"abstract":"<jats:p>Digital health interventions are increasingly used to support cardiovascular prevention, but their clinical maturity differs across risk factors and types of technology. This narrative review summarizes current evidence and implementation challenges related to digital therapeutics, mobile health applications, telemonitoring systems, and integrated digital health platforms in hypertension, dyslipidemia, and broader cardiometabolic prevention. The strongest evidence currently supports digitally enabled blood pressure management, particularly when home blood pressure monitoring, telemonitoring, behavioral support, medication adherence tools, and clinician-guided treatment adjustment are integrated into routine care. In contrast, digital interventions for dyslipidemia remain less established and are mainly focused on education, lifestyle modification, adherence support, shared decision-making, and long-term risk reduction. Therefore, most lipid-related digital tools should currently be interpreted as supportive mHealth or prevention interventions rather than fully established digital therapeutics. Successful implementation requires more than patient-facing applications. It depends on clinical workflow integration, professional responsibility for data review and telemonitoring alerts, regulatory and reimbursement pathways, data protection, interoperability, equity, and evidence of clinical and economic value. Future studies should distinguish between digital therapeutics, mHealth tools, telemonitoring systems, and digital ecosystems, and should evaluate clinically meaningful endpoints, safety, cost-effectiveness, and long-term sustainability.<\/jats:p>","DOI":"10.3389\/fdgth.2026.1915478","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:57:07Z","timestamp":1788335827000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Digital therapeutics and mHealth applications in cardiovascular prevention: strongest evidence in hypertension and emerging perspectives in dyslipidemia"],"prefix":"10.3389","volume":"8","author":[{"given":"Arkadiusz","family":"Wysocki","sequence":"first","affiliation":[{"name":"Department of Hypertension, Angiology and Internal Medicine, Poznan University of Medical Sciences","place":["Poznan, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Wierzowiecka","sequence":"additional","affiliation":[{"name":"Department of Hypertension, Angiology and Internal Medicine, Poznan University of Medical Sciences","place":["Poznan, Poland"]},{"name":"Institute of Neurological Disorders, Poznan University of Medical Sciences","place":["Pozna\u0144, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkadiusz","family":"Niklas","sequence":"additional","affiliation":[{"name":"Department of Hypertension, Angiology and Internal Medicine, Poznan University of Medical Sciences","place":["Poznan, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"B1","year":"2025"},{"key":"B2","year":"2024"},{"key":"B3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.5603\/ah.103916","article-title":"Guidelines for the management of hypertension in Poland 2024 \u2014 the position of the polish society of hypertension\/Polish cardiac society experts","volume":"28","author":"Prejbisz","year":"2024","journal-title":"Arterial Hypertension"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/eurjpc\/zwab154","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"29","author":"Visseren","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5603\/ah.99726","article-title":"Guidelines are one thing, practice is another. With newer and newer guidelines, why can\u2019t we manage to control modifiable cardiovascular risk factors?","volume":"28","author":"Wierzowiecka","year":"2024","journal-title":"Arterial Hypertension"},{"key":"B6","doi-asserted-by":"publisher","first-page":"658","DOI":"10.20452\/pamw.15013","article-title":"Blood pressure and cholesterol control in patients with hypertension and hypercholesterolemia: results from the polish national health survey WOBASZ II","volume":"129","author":"Niklas","year":"2019","journal-title":"Pol Arch Intern Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"642","DOI":"10.20452\/pamw.3464","article-title":"Changes in the prevalence, treatment, and control of hypercholesterolemia and other dyslipidemias over 10 years in Poland: the WOBASZ study","volume":"126","author":"Paj\u0105k","year":"2016","journal-title":"Pol Arch Med Wewn"},{"key":"B8","doi-asserted-by":"publisher","first-page":"662","DOI":"10.20452\/pamw.3499","article-title":"Prevalence of obesity and overweight among adults in Poland","volume":"126","author":"Stepaniak","year":"2016","journal-title":"Pol Arch Intern Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.20452\/pamw.3896","article-title":"Tobacco smoking in Poland in the years from 2003 to 2014. Multicentre national population health examination survey (WOBASZ)","volume":"127","author":"Polakowska","year":"2017","journal-title":"Pol Arch Intern Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e0156766","DOI":"10.1371\/journal.pone.0156766","article-title":"Ten-year changes in physical activity among polish adults: results of the WOBASZ I and II surveys","volume":"11","author":"Kwa\u015bniewska","year":"2016","journal-title":"PLoS One"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1038\/s41440-025-02481-9","article-title":"A multi-layer retrieval-augmented large language model framework for enhancing hypertension education","volume":"49","author":"Wang","year":"2026","journal-title":"Hypertens Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"951","DOI":"10.5114\/aoms.2017.72423","article-title":"Prevalence, awareness, treatment and control of hypertension in the adult polish population\u2014multi-center national population health examination surveys\u2014wOBASZ studies","volume":"14","author":"Niklas","year":"2018","journal-title":"Arch Med Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.1093\/eurheartj\/ehab559","article-title":"Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial","volume":"42","author":"Kario","year":"2021","journal-title":"Eur Heart J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1038\/s41440-022-01016-w","article-title":"The first software as medical device of evidence-based hypertension digital therapeutics for clinical practice","volume":"45","author":"Kario","year":"2022","journal-title":"Hypertens Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.mayocp.2024.09.018","article-title":"Self-monitoring of blood pressure and feedback via mobile app in treatment of uncontrolled hypertension: the SMART-BP randomized clinical trial","volume":"100","author":"Yoon","year":"2025","journal-title":"Mayo Clin Proc"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e52464","DOI":"10.2196\/52464","article-title":"Efficacy of a WeChat-based multimodal digital transformation management model in new-onset mild to moderate hypertension","volume":"25","author":"Wang","year":"2023","journal-title":"Randomized Clinical Trial J Med Internet Res"},{"key":"B17","article-title":"Newel Health obtains EU MDR for blood pressure management platform. Medical Device Network. June 9, 2025","author":"Law","year":""},{"key":"B18","article-title":"Amicomed","year":""},{"key":"B19","article-title":"Comarch e-Care 2.0 telemedicine platform","year":""},{"key":"B20","article-title":"CarnaLife System and digital medicine solutions","year":""},{"key":"B21","doi-asserted-by":"publisher","first-page":"e20456","DOI":"10.2196\/20456","article-title":"Readiness for voice technology in patients with cardiovascular diseases: cross-sectional study","volume":"22","author":"Kowalska","year":"2020","journal-title":"J Med Internet Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1038\/s41440-022-00952-x","article-title":"Cost-effectiveness of digital therapeutics for essential hypertension","volume":"45","author":"Nomura","year":"2022","journal-title":"Hypertens Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1161\/HYPERTENSIONAHA.118.12415","article-title":"Cost-effectiveness of telemonitoring and self-monitoring of blood pressure for antihypertensive titration in primary care (TASMINH4)","volume":"73","author":"Monahan","year":"2019","journal-title":"Hypertension"},{"key":"B24","year":""},{"key":"B25","doi-asserted-by":"publisher","first-page":"e011955","DOI":"10.1161\/JAHA.119.011955","article-title":"Corrie health platform for self-management after AMI","volume":"8","author":"Zhang","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"B26","article-title":"Corrie Lipids","year":""},{"key":"B27","article-title":"My A:Care","year":""},{"key":"B28","article-title":"CardioCube","year":""},{"key":"B29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41746-024-01423-y","article-title":"Impact of visual presentation of atherosclerotic carotid plaque on cardiovascular risk profile using mHealth technologies","volume":"8","author":"Ullrich","year":"2025","journal-title":"NPJ Digit Med"},{"key":"B30","year":""},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41746-022-00734-2","article-title":"The evolution of digital health technologies in cardiovascular disease research","volume":"6","author":"Zwack","year":"2023","journal-title":"NPJ Digit Med"},{"key":"B32","year":""},{"key":"B33","year":""},{"key":"B34","first-page":"120","article-title":"CoLipid: a mobile application for lipid monitoring","volume-title":"Int J Inter Mob Tech. (iJIM)","author":"Abdullah","year":"2024"}],"container-title":["Frontiers in Digital Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdgth.2026.1915478\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:57:08Z","timestamp":1788335828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdgth.2026.1915478\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":34,"alternative-id":["10.3389\/fdgth.2026.1915478"],"URL":"https:\/\/doi.org\/10.3389\/fdgth.2026.1915478","relation":{},"ISSN":["2673-253X"],"issn-type":[{"value":"2673-253X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"article-number":"1915478"}}